戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 s, and 7 with Stevens-Johnson syndrome/toxic epidermal necrolysis).
2 tiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis.
3 and a microRNA biomarker/mechanism for toxic epidermal necrolysis.
4 hylaxis, Stevens-Johnson syndrome, and toxic epidermal necrolysis.
5 disease, Stevens-Johnson syndrome, and toxic epidermal necrolysis.
6 ermatoses Stevens-Johnson syndrome and toxic epidermal necrolysis.
7 rogressing Stevens-Johnson syndrome or toxic epidermal necrolysis.
8 l Hospital, the national referral center for epidermal necrolysis.
9 ents with Stevens-Johnson syndrome and toxic epidermal necrolysis.
10 s sequalae to Stevens-Johnson syndrome/toxic epidermal necrolysis.
11 tment and Stevens-Johnson Syndrome and toxic epidermal necrolysis.
12 suspected Stevens-Johnson syndrome and toxic epidermal necrolysis.
13 tiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis), 2 months (drug eruption and eczem
14 patients with Stevens-Johnson syndrome/toxic epidermal necrolysis, 86 with drug reaction with eosinop
15 ontribute to the pathogenesis of ICI-induced epidermal necrolysis and provide potential therapeutic t
16 ide mediates the epidermal necrosis in toxic epidermal necrolysis and provides a potential target for
17                                        Toxic epidermal necrolysis and Stevens-Johnson syndrome are se
18  that a large burst of nitric oxide in toxic epidermal necrolysis and Stevens-Johnson syndrome may ca
19 ay rarely progress to life-threatening toxic epidermal necrolysis, and colitis, characterized by a mi
20 licated in the pathogenesis of eczema, toxic epidermal necrolysis, and drug-induced skin eruptions.
21 s (resulting from pneumococcal sepsis, toxic epidermal necrolysis, and renal failure) occurred at dos
22           Stevens-Johnson syndrome and toxic epidermal necrolysis are severe adverse cutaneous drug r
23 syndrome, and Stevens-Johnson syndrome/toxic epidermal necrolysis, can be severe and result in a dive
24 h include Stevens-Johnson syndrome and toxic epidermal necrolysis, drug reaction with eosinophilia an
25                    In-hospital mortality for epidermal necrolysis (EN) has been well-characterized, b
26 ing systems for Stevens-Johnson syndrome and epidermal necrolysis (EN) only estimate patient prognosi
27                             The incidence of epidermal necrolysis (EN), including Stevens-Johnson syn
28  erythema multiforme (IC(025) = 1.03), toxic epidermal necrolysis (IC(025) = 0.95), Stevens-Johnson s
29 e-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in specific Asian populations (incl
30                                              Epidermal necrolysis is a severe cutaneous adverse react
31 nt of either Stevens-Johnson syndrome, toxic epidermal necrolysis, or aplastic anemia.
32  admitted for Stevens-Johnson syndrome/toxic epidermal necrolysis over a 14-year period were included
33 n one of four Stevens-Johnson syndrome/toxic epidermal necrolysis patients and is associated with a p
34 tification of Stevens-Johnson syndrome/toxic epidermal necrolysis patients at higher risk of intubati
35                  A teenage survivor of toxic epidermal necrolysis presented with faint but diffuse dy
36 ugh rare, Stevens-Johnson syndrome and toxic epidermal necrolysis remain among the most devastating o
37 hod and the Algorithm for Drug Causality for Epidermal Necrolysis, respectively.
38             Algorithm for Drug Causality for Epidermal Necrolysis scoring was discordant in 28 cases,
39 sis, the Severity-of-Illness Score for Toxic Epidermal Necrolysis (SCORTEN), was recently found to ov
40 valuation of severity was the Score of Toxic Epidermal Necrolysis (SCORTEN), which ranges from 0 to 7
41 l-induced Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) and drug reaction with eo
42 s of disease, Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) and drug reaction with eo
43           Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis (SJS/TEN) are part of a disease con
44           Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) are rare but severe adver
45           Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) are severe cutaneous adve
46 ved in the Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN) group, whereas glaucoma w
47           Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) is a rare but life-threat
48               Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a severe hypersensitiv
49               Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is known to cause multipl
50 volved in Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN), although a detailed desc
51 ARs) such as Stevens-Johnson syndrome, toxic epidermal necrolysis (SJS/TEN), and drug reaction with e
52 CAR), such as Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), hindering continuous ICI
53  risk for Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN), which are the most sever
54 ons following Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN).
55 de life-threatening conditions such as toxic epidermal necrolysis, Stevens-Johnson syndrome, and hype
56  A search of PubMed using the keywords toxic epidermal necrolysis, Stevens-Johnson syndrome, photo-di
57        In the Stevens-Johnson syndrome/toxic epidermal necrolysis subgroup, significant associations
58 and Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) among carbamazepine users, es
59                                        Toxic epidermal necrolysis (TEN) and Stevens-Johnson Syndrome
60     Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening disorder
61     Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening mucocuta
62     Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but life-threatening
63     Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but life-threatening
64     Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but potentially life
65     Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe drug reactions ass
66 induced Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) as a model to study the patho
67     Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) cause diffuse epidermal detac
68 ted Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been infrequently report
69               We report a rare case of toxic epidermal necrolysis (TEN) in a 10-year-old boy with no
70                                        Toxic epidermal necrolysis (TEN) is a fatal drug-induced skin
71                                        Toxic epidermal necrolysis (TEN) is a severe adverse drug reac
72 f 200 patients with chronic ocular SJS/toxic epidermal necrolysis (TEN) were included in the study.
73        Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and graft-versus-host diseas
74 ing Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), could be life-threatening.
75 luding Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug rash with eosinophilia
76 uch as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), or drug rash with eosinophil
77 ocular Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), or SJS/TEN was performed.
78 ing Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), varies across studies.
79 ons Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).
80  as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).
81   The most commonly used prognostic score in epidermal necrolysis, the Severity-of-Illness Score for
82 s and in-hospital mortality in patients with epidermal necrolysis to study the incremental prognostic
83 hod and the Algorithm for Drug Causality for Epidermal Necrolysis was highly probable or probable in
84               Stevens-Johnson syndrome/toxic epidermal necrolysis was the most common indication (49.
85                 A total of 196 patients with epidermal necrolysis were recruited, 4 (2%) of whom were
86 e child in the placebo group had fatal toxic epidermal necrolysis with concurrent Pseudomonas aerugin